Solvonis Therapeutics Advances Acquisition of Awakn Life Sciences

The latest update is out from Graft Polymer (UK) PLC ( (GB:SVNS) ).

Solvonis Therapeutics plc announced that all resolutions related to its proposed acquisition of Awakn Life Sciences Corp. were approved at a recent General Meeting. This acquisition is a significant step in Solvonis’ strategy to address unmet needs in mental health and addiction treatment, particularly targeting Alcohol Use Disorder (AUD) with two clinical-stage assets, AWKN-001 and AWKN-002. The acquisition, pending regulatory and court approvals, is expected to complete by the end of May 2025, potentially enhancing Solvonis’ market position in the biotechnology sector.

More about Graft Polymer (UK) PLC

Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property related to the treatment of mental health and substance use disorders. The company is co-developing therapeutics for mental health disorders with an initial focus on trauma-related conditions such as PTSD, which affects millions across the U.S., UK, and EU markets.

YTD Price Performance: -25.85%

Average Trading Volume: 8,524,556

Technical Sentiment Signal: Buy

Current Market Cap: £3.5M

For a thorough assessment of SVNS stock, go to TipRanks’ Stock Analysis page.